Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Zacks·2d ago
More News
Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil
VKTX posts a wider Q3 loss and no sales, as R&D costs surge and obesity drug studies drive spending higher.
Zacks·5d ago
Viking Therapeutics Stock Soars After Morgan Stanley’s Price Target Implies A Potential 225% Upside
Stocktwits·6d ago
Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?
Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.
Zacks·6d ago
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q3 Results?
Novo Nordisk's Q3 results hinge on Ozempic and Wegovy sales as demand growth slows amid rivalry, market limits and compounded drug headwinds.
Zacks·6d ago
Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR...
PR Newswire·6d ago
Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity
Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in...
PR Newswire·8d ago
Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $33.54, denoting a -3.44% move from the preceding trading day.
Zacks·11d ago
Pre-Q3 Earnings: Is Viking Therapeutics Stock a Portfolio Must-Have?
VKTX is likely to have headed into Q3 earnings with no product revenue, pipeline updates in focus and widening loss forecasts testing investor patience.
Zacks·12d ago
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and Viking Therapeutics
Eli Lilly's blockbuster GLP-1 drugs, Mounjaro and Zepbound, are driving explosive growth as the company prepares to report Q3 results.